Nuveen’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$18.3M Buy
217,482
+26,867
+14% +$1.56M ﹤0.01% 1190
2025
Q4
$7.86M Buy
190,615
+147,374
+341% +$5.71M ﹤0.01% 1697
2025
Q3
$1.7M Sell
43,241
-4,452
-9% -$114K ﹤0.01% 2364
2025
Q2
$889K Sell
47,693
-16,688
-26% -$313K ﹤0.01% 2664
2025
Q1
$1.17M Sell
64,381
-1,470
-2% -$32.4K ﹤0.01% 2576
2024
Q4
$1.44M Hold
65,851
﹤0.01% 2527
2024
Q3
$1.8M Sell
65,851
-20,920
-24% -$583K ﹤0.01% 2465
2024
Q2
$2.25M Buy
+86,771
New +$2.09M ﹤0.01% 2326
2022
Q2
Sell
-4,417
Closed -$238K 3307
2022
Q1
$238K Hold
4,417
﹤0.01% 3158
2021
Q4
$339K Sell
4,417
-1,168
-21% -$117K ﹤0.01% 3154
2021
Q3
$697K Buy
5,585
+81
+1% +$9.44K ﹤0.01% 3103
2021
Q2
$861K Sell
5,504
-3,059
-36% -$562K ﹤0.01% 3058
2021
Q1
$1.62M Sell
8,563
-416
-5% -$70K ﹤0.01% 2710
2020
Q4
$1.13M Buy
8,979
+949
+12% +$108K ﹤0.01% 2757
2020
Q3
$873K Buy
8,030
+3,938
+96% +$467K ﹤0.01% 2741
2020
Q2
$492K Sell
4,092
-134
-3% -$18.9K ﹤0.01% 2903
2020
Q1
$425K Buy
4,226
+1,004
+31% +$186K ﹤0.01% 2826
2019
Q4
$782K Sell
3,222
-104
-3% -$19.4K ﹤0.01% 2774
2019
Q3
$546K Hold
3,326
﹤0.01% 2916
2019
Q2
$785K Buy
+3,326
New +$822K ﹤0.01% 2832

Other funds holding DNTH

Nuveen's DNTH Position: Q1 2026 in Review

Nuveen increased its Dianthus Therapeutics (DNTH) stake by 14% in Q1 2026, buying an estimated $1.56M and bringing the position to 217,482 shares worth $18.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1190.

Nuveen first reported a position in DNTH in Q2 2019 and has held it in 20 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Nuveen held 217,482 shares of Dianthus Therapeutics worth $18.3M as of Q1 2026.
  • Nuveen bought 26,867 Dianthus Therapeutics shares in Q1 2026, an estimated $1.56M.
  • Dianthus Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1190 holding.
  • Nuveen first reported a position in Dianthus Therapeutics in Q2 2019 and has held it in 20 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.